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Objectives: Ascorbic (AA) and uric (UA) acids act as antioxidants and are capable to react with biological-
ly relevant oxidants. We aimed to developed a simple, rapid, sensitive, and accurate ion-exclusion HPLC-UV
methodology for the simultaneously determination of AA and UA in human plasma.
Methods: Analytical pre-requisites, such as the use of heparin as an anticoagulant and meta-phosphoric
acid as a stabilizer were added for accurate and reliable measurements.
Chromatographic separation was achieved by an isocratic elution on a HEMA-BIO 1000 SB analytical column
using a phosphate buffer, pH 2.4, as a mobile phase.
Results: Results indicated an excellent linearity with correlation coefﬁcients (r2)≥0.999. The LOD of AA
and UA was 1.02 and 1.42 nmol/mL, respectively, while LOQ ranged from 0.306 to 0.426 nmol/mL. A great
repeatability for both antioxidants was found, where the CV (%) values for intra-day were lower than 1.8%
and under 6.5% for the inter-day assay. The recovery of AA ranged from 92% to 96% and from 99% to 100%
for UA.
Conclusion: This validated method allows the determination of both antioxidants within 10 min, and is
well suited to routine measurements and/or high-throughput clinical analysis. The methodology was applied
to assess the antioxidant status of a group of Azorean subjects.
© 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Introduction
Atherosclerosis (AT), hardening and narrowing of the arteries, is the
major cause of cardiovascular disease (CVD), and is a multifactor pro-
gressive pathological process where inﬂammation and oxidative pro-
cesses have a central role, from fatty streak formation to plaque
rupture and thrombosis [1]. Several studies suggested that the oxida-
tion of low-density lipoprotein (LDL)-cholesterol may play an impor-
tant role in promoting premature AT. According to the oxidative-
modiﬁcation hypothesis of atherogenesis, LDL-cholesterol in its native
state is not atherogenic. However, LDL-cholesterol particleswill become
atherogenic and initiate the atherosclerotic silent process, with the for-
mation of foam cells, if they are oxidatively modiﬁed [2]. The antioxi-
dant content of LDL-cholesterol is critical for its protection. As a result,
the balance between the pro-oxidant challenge and the presence of an-
tioxidants determines the extent of the arterial wall modiﬁcation [3,4].
Antioxidants such as ascorbic acid (AA) and uric acid (UA) (Fig. 1)
participate in defense mechanisms against oxidative damage as free
radical scavengers [5].
L-Ascorbic acid (vitamin C) is a water-soluble vitamin which is in-
volved in several biochemical reactions in cells and tissues [6]. Under
physiological conditions, AA is an electron donor, which allows it to
react with biologically relevant radicals and other oxidants such as
superoxide anion, hydroxyl radical, singlet oxygen and hypochlorous
acid [7]. Furthermore, it can regenerate vitamin E (α-tocopherol) from
both α-tocopheryl radical and tocophrylquinone in membranes [7]. Vi-
tamin C also acts as a cofactor for enzymes involved in the biosynthesis
of collagen and carnitine, participates in the conversion of neurotrans-
mitter dopamine to norepinephrine and in the metabolism of tyrosine
[8], and is involved in the absorption of iron from non-heme sources
from intestine [6]. Almost all animals are able to endogenously synthe-
size large quantities of vitamin C. However, humans lost this ability as a
result of a series of inactivating mutations of the gene encoding
gulonolactone oxidase (GULO), the rate limiting enzyme in the vitamin
C biosynthetic pathway. Therefore, to compensate, humans must con-
sume exogenous vitamin C on a daily basis, from a variety of dietary
sources as fruit and vegetables [7,9,10].
UA is the end product of endogenous and dietary purine nucleo-
tide metabolism in humans. It is derived from xanthine, which, in
turn, results from hypoxanthine, being both reactions catalyzed by
xanthine oxidase [11,12]. In most species, UA is further metabolized
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to allantoin by the urate oxidase (uricase) enzyme, but humans lack
this enzyme because of a defective gene that is not transcribed
[13,14]. Therefore, UA is excreted in urine, and plasma UA levels in
humans are appreciably higher as compared to those in most mam-
mals. Studies in vitro have pointed out the important role of uric
acid as an antioxidant substance, acting as a potent scavenger of sin-
glet oxygen and hydroxyl radicals and as a chelator of transitional
metal ions which are thus converted to poorly reactive forms [12,15].
Several methods have been presented by different researchers for
the determination of ascorbic and uric acids in biological samples
such as: spectrophotometric methods, high performance liquid chro-
matography (HPLC) with electrochemical (EC) or ultraviolet (UV) de-
tection [16,17], and capillary electrophoresis (CE) coupled with UV
[18] or EC [19]. However, only a few studies have described the simul-
taneous determination of AA and UA. Several pre-analytical procedures
are required for an accurate and reliable determination of these two an-
tioxidants in human plasma, mainly because AA is extremely sensitive
to oxidation and degradation during blood sampling, handling, storage,
and analysis [20,21]. Additionally, it is necessary to stabilize the plasma
samples by protecting them from light and high temperatures, as well
as acidifying the samples before storage, particularly when it is not pos-
sible to immediately perform the analysis. According to Lykkesfeldt [22]
the blood collection, including the anticoagulant used, have consider-
able inﬂuence on the outcome data.
The aim of the present study was the development of a simple,
rapid, sensitive, precise, and accurate ion-exclusion HPLC-UV method-
ology (isocratic elution) for the simultaneously determination of AA
and UA to be applied to blood samples donated by Azorean subjects
with no declared chronic diseases.
Materials and methods
Chemicals
L(+)-Ascorbic acid, dehydro-L-ascorbic acid (DHAA), perchloric
acid (PCA), and acetonitrile were purchased from Sigma-Aldrich
(Sigma-Aldrich Chemie, Steinheim, Germany). Meta-phosphoric acid
(MPA), trichloroacetic acid (TCA), sodium dihydrogen phosphate
(NaH2PO4), and dodecyltrimethyl ammonium chloride were obtained
from Fluka (Sigma-Aldrich Chemie, Steinheim, Germany). Potassium
dihydrogeno phosphate (KH2PO4), uric acid, and ortho-phosphoric acid
were provided by Merck (Darmstadt, Germany). Sodium hydroxide
(NaOH) and ethylenediaminetetraacetic acid disodium (Na2EDTA)
were obtained from Riedel-de Haën (Sigma-Aldrich Chemie, Steinheim,
Germany). Deionized water obtained from an in-house Milli-Q water
puriﬁcation system (Millipore, Bedford, MA, USA) was used for the
preparation of themobile phase and the standard solutions. All solvents
were HPLC grade and standards of the highest purity available.
Blood samples
Stability is a key problem of AA blood analysis, because AA is rapidly
degraded to DHAA (Fig. 1). Both AA oxidation and DHAA hydrolysis are
further prevented to some extent by acidiﬁcation. Acids as PCA, TCA,
and MPA have been investigated for the AA stabilization [23,24]. How-
ever, MPA showed to be more efﬁcient, considering both stabilization
of AA and DHAA and precipitation of plasma sample proteins. MPA
was adopted in our study because it also showed the ability to separate
from AAwith superior resolution and left lower level of contamination.
Whole blood samples were collected from 321 (187 women and
134 men) subjects (under fasting conditions) whom consented to
participate in this study. Venous blood was drawn in heparinised
vacutainers Sarstedt (Sarstedt AG & Co., Nümbrecht, Germany) by a
standardized procedure of venipucture. The individuals were selected
under the following criteria: apparently healthywith no declared chron-
ic diseases (including diabetes and CVD), aged 20 to 60 years, all born
and living in the Azores Archipelago (Portugal). Subjects that had been
taking vitamin supplementswere excluded from the study. The study re-
ceived ethical committee approval of our institution and all participants
provided written informed consent.
Plasmawas generated by immediately centrifugation at 2500 ×g for
15 min at 4 °C. One aliquot of plasma in an opaque Eppendorf tube was
exhaustively vortexed with cold freshly prepared 10% MPA (1:1; v/v)
for 30 s, and stored at−80 °C until further analysis. For the quantiﬁca-
tion of the analytes, thawed plasma samples were vortexed and then
centrifuged at 16,000 ×g for 15 min at 4 °C. One aliquot of 20 μL from
the clear supernatant was promptly used for chromatographic analysis.
All the procedures were performed under light protection.
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Fig. 1. Chemical structures: a) oxidation and reduction of ascorbic acid and b) uric acid.
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Standards preparation and calibration curves
A standard stock solution containing 5 mmol/L of AA was freshly,
daily prepared in Milli-Q water. The working standard solutions of AA
were prepared by diluting the stock solution with Milli-Q water, cov-
ering the range of 0–200 (0, 5, 15, 25, 50, 75, 100, 150, 200) μmol/L
analyzing each working standard solution in quadruplicate. The stock
solution of UA was freshly prepared at 1.2 mmol/L by dissolving in
20 mmol/L NaOH. The working standard solutions of UA ranged from
0 to 500 (0, 10, 30, 60, 120, 200, 300, 400, 500) μmol/L, and were pre-
pared by appropriately diluted stock solution with 20 mmol/L NaOH.
All daily prepared stock and working standard solutions were carefully
protected from light during preparation and analyses, and were also
maintained in ice. The multicalibration curves were constructed by
plotting the peak area of each analyte against concentration which
gave the values of the slope alongwith the intercept and correlation co-
efﬁcient for each calibration curve.
Chromatographic conditions
Plasma sample analyseswere carriedoutwith anAgilent Technologies
(Avondale, PA, USA) HPLC model 1200 system with UV (DAD) detector.
Two different types of reversed phase columns, with different degrees
of hydrophobicity and different carbon loadings were initially tested for
the MPA, AA and UA separation from the other plasma components.
The separation was investigated, for the best resolution, using mobile
phases with different ratios of organic phase to aqueous phase and differ-
ent pH values. In order to achieve a complete separation, particularly
between MPA and AA, a ﬁne-tuning resolution was performed with
Chromolith Performance RP18-5 μm (100 mm×4.6 mm I.D.) column
coupled with a Chromolith Performance RP18-5 μm (10 mm×4.6 mm)
guard column, provided by Phenomenex (Torrence, CA, USA), following
themethodology of Karlsen et al. [25] with slightlymodiﬁcation. Themo-
bile phase was prepared by addition of 2% acetonitrile to the aqueous
phase (2.5 mmol/L NaH2PO4, 2.5 mmol/L dodecyltrimethyl ammonium
chloride and 1.25 mmol/L Na2EDTA in milli-Q water). The ﬂow rate was
0.6 mL/min. The injection volume used was 5 μL. A variable wavelength
DAD detector was used at 264 nm. The results of these experiments
have shown a partially overlapped MPA and AA signals that compromise
the quantiﬁcation accuracy. In order to improve the separation the
present method was developed using an HEMA-BIO 1000 SB analyt-
ical column (250×4.6 mm I.D., 10 μm particle size; obtained from
Tessek, Ltd., Prague, Czech Republic) protected by a OnyxMonolithic
C18 guard-column (10×4.6 mm, I.D.; provided by Phenomenex,
Torrence, CA, USA). The mobile phase consisted of 20 mmol/L KH2PO4,
pH 2.4, after ﬁltration through a 0.45 μm cellulose acetate membrane
Whatman (Dassel, Germany). The temperature of the column oven
was maintained at 35 °C, and the ﬂow rate used was 0.50 mL/min. An
aliquot of 20 μL was injected through a Rheodyne 71251 injection
valve ﬁtted with a 20 μL sample loop (Rheodyne, Cotati, CA, USA). For
UV-detection the wavelength (DAD) was set at 245 nm. The quantita-
tive determinations were achieved by using the external standard
methodwith the Agilent Technologies ChemStation software andwork-
ing standard solutions of the analytes. The sample concentration was
limited to the linearity range in order to avoid peak tailing and retention
time shifting, which may occur when the sample amount approaches
the column sample load capacity. Results were expressed as μmol/mL
of plasma and all analysis were performed in triplicate. The chromato-
grams were recorded according to the retention time.
Method validation
The analytical method was validated taking into consideration the
precision, repeatability, speciﬁcity, sensitivity, linearity within the re-
ferred concentration ranges, and recovery [26].
The precision of the chromatographic methodology was evaluated
by performing intra- and inter-day multiple injections of AA and UA
standard solutionswith three different concentrations, and by checking
the percentages of the coefﬁcient of variation of the peak area. The spec-
iﬁcity of the method was tested by co-elution of AA and UA with au-
thentic standards and by spectral comparison with standards using
the diode-array detector. The sensitivity of themethodwas determined
by quantifying the limit of detection (LOD) that was evaluated using a
lower analyte concentration that would yield a signal-to-noise ratio
(S/N) of 3; the limit of quantiﬁcation (LOQ) represents the analyte con-
centration thatwould yield a signal-to-noise (S/N) of 10. The linearity of
the method was investigated with the use of AA and UA calibration
curves from freshly standard solutionswithin the expected and exceed-
ing concentration ranges. The accuracy of thismethodwas evaluated by
determining the recovery of AA and UA in sampleswith known amounts
of these two antioxidants. Three different known amounts of each stan-
dard compound were added to the plasma sample which was subjected
to the HPLC chromatographic analysis. The recovery was calculated
based on the difference between the total concentration determined in
the spiked samples and the concentration observed in the non-spiked
samples. All analyses were carried out in triplicate.
Statistical analysis
Statistical analysis was performed by using SPSS 15.0 for software
for windows (SPSS Institute, Chicago, IL). Linear regression was applied
to develop an equation to predict the AA andUAplasma concentrations.
Differences between men and women were tested by Student's t-test
and data are presented as mean±SD. A P-value of b0.05 was consid-
ered to be statistically signiﬁcant.
Results and discussion
Sample preparation
For a reliable and correct chromatographic separation of AA and UA
from plasma, it is required to take pre-analytical procedures since sta-
bility is a crucial problem for these antioxidants. The whole blood sam-
ples must be collected into vacutainer tubes containing heparin as
anticoagulant [25,27,28], and must be kept in the dark and at +4 °C
until plasma was separated from cells, since temperature, light, and
the presence or absence of oxygen induces the analytes' degradation
[29]. Immediately after the centrifugation, plasma samples were acidi-
ﬁed with meta-phosphoric acid to stabilize the sample before storage
at −80 °C since measurements could be performed within this time
[27].
Chromatographic separation
A representative HPLC chromatogram of the human plasma sample
obtained is shown in Fig. 2. Retention times for AA and UA were
6.056 min and 8.463 min, respectively. The identiﬁcation of the peaks
was done by comparison of the retention times with those correspond-
ing to the pure standards ran separately in the same analytical condi-
tions, conﬁrmed by spike of the authentic standards to the plasma
sample and by spectral comparison with standards using the DAD pro-
ﬁle between 200 and 400 nm. The isocratic elution of the two analytes
was completed within 10 min (Fig. 2), allowing a new injection every
12 min and consequently a high-throughput HPLC analyses. The com-
plete chromatographic separation of the three analytes (MPA, AA and
UA), particularly between MPA and AA, was successfully achieved
using the HEMA-BIO 1000 SB, a strong cation exchange analytical col-
umn containing sulphobuthly groups. These groups are bound to a hy-
drophilic hydroxyethyl methacrylate backbone. The retention on the
ion-exchange columns is controlled by electrostatic attraction and/or
repulsion forces, hydrophobic interactions and the size-exclusion effect
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by partial penetration into the pores [28]. In our study, MPA that is ion-
ized at the pH of the mobile phase is excluded from the ionic functional
group\SO3− in the column, reducing its retention time and allowing a
better separation from AA and UA that are protonated at the mobile
phase pH. The column stability at the very low mobile phase pH is
assured by the polymeric matrix of the stationary phase. In addition,
this AA and UA plasma separation method has the advantage of saving
time and volume of mobile phase that are of crucial importance for rou-
tine analysis. Under these elution conditions, all the peaks of interest
were well separated and there were no other interfering peaks from
the plasma.
Method validation
The validating parameters for both calibration curves (slope, intercept,
correlation coefﬁcient) aswell as for the linear range are shown in Table 1.
Results indicated an excellent linearity for both analytes over the referred
concentration rangeswith correlation coefﬁcients (r2)≥0.999. The LODof
the assay (at a signal-to-noise ratio of 3) for AA and UA was 1.02 and
1.42 nmol/mL, respectively, while the LOQ (a signal-to-noise ratio of
10) ranged from 0.306 to 0.426 nmol/mL. The precision of isocratic
HPLC-UV methodology was evaluated by performing intra- and
inter-day multiple injections of AA and UA standard solutions with
three different concentrations and by checking the percentages of coef-
ﬁcient of variation of the peak area. The results presented in Table 2 re-
vealed a great repeatability for both antioxidants, since the CV (%)
values for intra-day were lower than 1.8% and under 6.5% for the
inter-day. The assessment of the analytical recovery was based on the
difference between the total concentration determined in the spiked
plasma samples and the concentration in the non-spiked samples
(Table 3). Three different known amounts of AA and UA authentic stan-
dards were added to the plasma samples (n=3) whichwere subjected
to the chromatographic analysis. Table 3 shows the good recovery for
both antioxidants. For AA the recovery ranged from 92% to 96% and
for UA from 99% to 100%. Regarding the validation parameters we can-
not compare our resultswith others reported in literature. The fewpub-
lished results for the simultaneous determination of AA and UA plasma
levels used different separation methods (capillary electrophoresis and
RP-HPLC-ECD) [16,18]. Our methodology shows that it is possible to
accurately determine the amount of AA and UA in plasma samples by
HPLC with UV detection, which does not agree with Li and Franke [16]
who reported that HPLC-UV is not suitable for plasma AA determination.
Application of the method
The presented methodology was employed for the assessment of
AA and UA levels in 321 plasma samples from subjects with no de-
clared chronic diseases. The mean values for the concentrations of
Fig. 2. HPLC chromatogram obtained from the analysis of plasma sample with UV detection. Chromatographic conditions: HEMA-BIO 1000 SB column (250×4.6 mm I.D., 10 μm);
Mobile phase: isocratic elution with 20 mmol/L KH2PO4 buffer pH 2.4 and the ﬂow rate was 0.50 mL/min; temperature 35 °C; UV detection (λ=245 nm). Legend:
meta-phosphoric acid — MPA (3.704 min), ascorbic acid — AA (6.056 min), and uric acid — UA (8.463 min).
Table 1
The regression equations, the linear range and the limits of detection and quantiﬁca-
tion of plasma ascorbic acid (AA) and uric acid (UA).
Analytes Linear range
(μmol/L)
Linear equation r2a LODb
(nmol/mL)
LOQc
(nmol/mL)
AA 5–200 y=20.822x−14.629 0.999 0.306 1.02
UA 10–500 y=0.6052x−0.6193 0.999 0.426 1.42
a r2 — correlation coefﬁcient.
b LOD — limit of detection.
c LOQ — limit of quantiﬁcation.
Table 2
Intra- and inter-day (n=10) precision data for peak area (mean±SD), and coefﬁcient
of variation (CV) of three different concentrations of ascorbic (AA) and uric (UA) acids.
Analytes Standard
concentration
(μmol/L)
Intra-day precision
(n=10)
Inter-day precision
(n=10)
Mean±SD CV
(%)a
Mean±SD CV
(%)a
AA 15 293.029±3.94 1.34 304.152±13.76 4.52
25 496.689±0.44 0.09 521.579±28.74 5.51
75 1520.214±0.63 0.04 1508.263±14.20 0.94
UA 30 372.229±0.32 0.09 371.882±9.41 2.53
60 770.541±5.27 0.68 776.683±18.86 2.43
200 2580.655±45.79 1.77 2446.316±158.82 6.49
a CV(%)=(SD/Mean)×100.
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AA and UA are illustrated in Table 4. The revealed values for both an-
tioxidants are within the reference range as compared with reported
results in literature [30,31]. AA concentrations were signiﬁcantly higher
(17%) inwomen than inmen (Pb0.001), whereasUA levelswere signif-
icantly higher (51%) in men as compared to women (Pb0.001).
Conclusion
The HEMA-BIO 1000 SB analytical column showed the ability to
separate AA and UA from MPA with superior resolution as compared
with the reversed phase C18 column. A validated and rapid isocratic
HPLC-UV method was successfully developed for the simultaneous
determination of AA and UA levels in human plasma. The methodology
offers great sensitivity, precision, accuracy and reproducibility for the
determination of both antioxidants within 10 min, and is well suited
to routine measurements and/or high-throughput clinical analysis.
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50 80.0±6.2 95±0.8 0.85
UA 137.3±26.7 30 167.4±25.5 100±1.1 1.10
60 196.8±23.4 100±1.7 1.70
120 254.0±23.3 99±1.5 1.51
Table 4
Ascorbic (AA) and uric (UA) acids plasma levels in the apparently healthy subjects,
according to gender.
Antioxidants (μmol/L) All a Womena Mena
(321) (187) (134)
AA 53±23 56±23 48±23⁎⁎⁎
UA 209±89 171±65 259±93⁎⁎⁎
a Values are mean±SD for (n) subjects; asterisks denote signiﬁcant differences be-
tween gender.
⁎⁎⁎ Pb0.001.
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